Recombinant ZIKV E antibody

Catalog No. ABIN6253501

Product Details anti-ZIKV E Antibody

Target: ZIKV E (Zika Virus Envelope (ZIKV E))

Antibody Type: Recombinant Antibody

Reactivity: Zika Virus (ZIKV)

Host: Human

Clonality: Monoclonal

Conjugate: This ZIKV E antibody is un-conjugated

Application: Functional Studies (Func)

Purpose: anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)

Characteristics: Recombinant Antibody. Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E). Species cross-reactivity: Virus. Clone: ZKA64. Isotype: Human IgG1kappa. Applications: FUNC, FUNC (Blocking). Host: . Liquid. In PBS. The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.

Purity: >95 % (SDS-PAGE)

Endotoxin Level: <0.001EU/μg

Immunogen: Zika Virus

Clone: ZKA64

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: Liquid. In PBS.

Preservative: Without preservative

Handling Advice: Avoid freeze/thaw cycles.

Storage: 4 °C,-20 °C

Storage Comment:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.

Target Details for ZIKV E

Target: ZIKV E (Zika Virus Envelope (ZIKV E))

Alternative Name: Zika Virus Envelope Protein (ZIKV E Products)

Target Type: Viral Protein

Background:

Alternate Names/Synonyms: ZIKV E Protein

Product Description: The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.